Crizotinib-d9

• Description:

  Crizotinib-d9 (PF-02341066-d9) is deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition[1][2][3].

• Product Name Alternative:

  PF-02341066-d9

• UNSPSC:

  12352005

• Target:

  Isotope-Labeled Compounds

• Related Pathways:

  Others

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Smiles:

  C[C@H](C1=C(C(F)=CC=C1Cl)Cl)OC2=CC(C3=CN(C4([2H])C([2H])([2H])C([2H])([2H])NC([2H])([2H])C4([2H])[2H])N=C3)=CN=C2N

• Molecular Formula:

  C21H13D9Cl2FN5O

• Molecular Weight:

  459.39

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• CAS Number:

  [1523580-59-7]